A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Phase 2 Unknown 18 enrolled Oncotelic Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.

Timeline

Start: 2021-04
Primary completion: 2021-08
Completion: 2021-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	trabedersen	Antisense oligonucleotide	140 mg/m2	Intravenous
Background	Artemisinin	Small molecule	500 mg	Oral

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Summary

Timeline

Drugs

Indications